secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vera Therapeutics, Inc. (VERA)
CIK:        0001831828
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0000950170-22-023518
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vera Therapeutics Q3 net loss $24.7M; cash $114.4M; atacicept Ph2b ORIGIN data early Q1 2023
--------------------------------------------------------------------------------

- Net loss of $24.7M ($0.91 per share) vs $7.6M loss YoY; cash burn $46.4M YTD.
- Cash, equivalents, and marketable securities $114.4M; additional $20M drawn from credit facility in Nov 2022; funds operations to Q2 2024.
- Phase 2b ORIGIN trial of atacicept in IgA nephropathy topline data expected early Q1 2023.
- Initiated pivotal Phase 3 COMPASS trial of atacicept in lupus nephritis.
- Positive Phase 2 MAU868 results in BK viremia presented; plan to start Ph2b/Ph3 trial in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831828/000095017022023518/0000950170-22-023518-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831828/000095017022023518/vera-20221109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-023518

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer